Inozyme Pharma
We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these metabolites. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
321 Summer St Suite #400
Boston, MA 02210
Boston, MA 02210
-
“At Inozyme, keeping the patient and family at the center of our work is the foundation of everything we do. Including the patient voice in our research leads to stronger clinical trials, and ultimately, potential therapeutic options that can improve the lives of patients living with rare disorders.”
Catherine Nester
SVP HCP and Patient Engagement
NEWS
The new year began with a fairly low level of clinical trial news. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
The $49M in Series A funding will be used to develop the company’s enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the clinic.
JOBS
IN THE PRESS